Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – January 2011

Pages: 68 Published: January 12, 2011 Report Code: GDPH0186MD

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals January 2011” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in December 2010. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry. Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

Analysis of the market trends for the pharmaceutical industry in the global arena.

Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.

Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.

Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.

Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.

Analysis of partnership and licensing deals based on clinical stage of development of products.

Summary of the pharmaceutical deals globally in the last six months.

Information on the top deals happened in the pharmaceutical industry.

Geographies covered include North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to Buy

Enhance your decision making capability in a more rapid and time sensitive manner.

Find out the major deal performing segments for investments in your industry.

Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.

Identify companies that are aggressively looking to raise capital in the market

Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.

Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.

Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.

Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.

Identify growth segments and opportunities in each region within the industry.

Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Table of Contents

1 0BTable of contents

T1T TTable of contentsT 2

T1.1T TList of TablesT 4

T1.2T TList of FiguresT 6

T2T TDeal SummaryT 8

T2.1T TPharmaceuticals & Healthcare, Global, Deals Analysis, December 2010T 8

T2.2T TPharmaceuticals & Healthcare, Global, Top Deals, December 2010T 10

T2.2.1T TNovartis Receives Alcon's Board Approval For The Acquisition Of Remaining 23% StakeT 10

T2.2.2T TThermo Fisher Scientific To Acquire DionexT 10

T2.2.3T TCephalon Enters Into Licensing Agreement With MesoblastT 10

T2.2.4T THypermarcas To Acquire Mantecorp Industria Quimica e FarmaceuticaT 11

T2.2.5T TCVS Caremark To Acquire Universal AmericanT 11

T2.3T TPharmaceuticals and Healthcare, Global, by Type, Number of Deals and Deal Values, December 2010T 12

T3T TPharmaceuticals and Healthcare, Deals Summary, by TypeT 13

T3.1T TPharmaceuticals and Healthcare, Global, M&A, December 2010T 13

T3.1.1T TTop M&A Deals in December 2010T 14

T3.1.2T TPharmaceuticals and Healthcare, Global, M&A Deals by Therapy Area, July 2010 – December 2010T 14

T3.2T TPharmaceuticals and Healthcare, Global, Equity Offering Deals, December 2010T 16

T3.2.1T TTop Equity Offering Deals in December 2010T 17

T3.2.2T TPharmaceuticals and Healthcare, Global, Equity Offering Deals by Therapy Area, July 2010 – December 2010T 17

T3.3T TPharmaceuticals and Healthcare, Global, Debt Offering Deals, December 2010T 19

T3.3.1T TTop Debt Offering Deals in December 2010T 20

T3.3.2T TPharmaceuticals and Healthcare, Global, Debt Offering Deals, by Therapy Area, July 2010 – December 2010T 21

T3.4T TPharmaceuticals and Healthcare, Global, Private Equity and Venture Capital Deals, December 2010T 22

T3.4.1T TTop PE/VC Deals in December 2010T 23

T3.4.2T TPharmaceuticals and Healthcare, Global, PE/VC by Therapy Area, December 2010T 24

T3.4.3T TPharmaceuticals and Healthcare, Global, Venture Capital Deals by Stage of Financing, December 2010T 25

T3.4.4T TPharmaceuticals and Healthcare, Global, Top Venture Financing Firms, July 2010 – December 2010T 26

T3.4.5T TPharmaceuticals and Healthcare, Global, Top VC Backed Companies, July 2010 – December 2010T 27

T4T TPharmaceuticals and Healthcare, Global, Partnership Deals, December 2010T 28

T4.1T TPharmaceuticals and Healthcare, Global, Partnership Deals, December 2010T 28

T4.2T TPharmaceuticals and Healthcare, Global, Partnership Deals by Therapy Area, July 2010 – December 2010T 29

T4.3T TPharmaceuticals and Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), December 2010T 30

T4.3.1T TPharmaceuticals and Healthcare, Global, Top Partnership Deals by Payment Mode, December 2010T 31

T4.4T TPharmaceuticals and Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), July 2010 – December 2010T 32

T4.5T TPharmaceuticals and Healthcare, Global, Partnership Deals by Phase, Number Of Deals and Deal Values (US$ m), July 2010 – December 2010T 33

T4.6T TPharmaceuticals and Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), July 2010 – December 2010T 34

T5T TPharmaceuticals and Healthcare, Global, Licensing Agreements, December 2010T 35

T5.1T TPharmaceuticals and Healthcare, Global, Licensing Agreements, December 2010T 35

T5.2T TPharmaceuticals and Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), December 2010T 36

T5.2.1T TPharmaceuticals and Healthcare, Global, Top Licensing Agreements by Deal Value, December 2010T 37

T5.2.2T TPharmaceuticals and Healthcare, Global, Top Licensing Agreements, by Total Upfront Payment, December 2010T 37

T5.2.3T TPharmaceuticals and Healthcare, Global, Top Licensing Agreements by Total Milestone Payments, December 2010T 38

T5.3T TPharmaceuticals and Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal values (US$ m), July 2010 – December 2010T 39

T5.4T TPharmaceuticals and Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), July 2010 – December 2010T 40

T5.5T TPharmaceuticals and Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), July 2010 – December 2010T 41

T5.6T TPharmaceuticals and Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), July 2010 – December 2010T 42

T6T TDeal Summary by Therapy AreaT 43

T6.1T TPharmaceuticals and Healthcare, Global, Oncology Deals, December 2010T 43

T6.1.1T TOncology – Deals of the MonthT 44

T6.2T TPharmaceuticals and Healthcare, Global, Central Nervous System Deals, December 2010T 45

T6.2.1T TCentral Nervous System – Deals of the MonthT 46

T6.3T TPharmaceuticals and Healthcare, Global, Infectious Disease Deals, December 2010T 47

T6.3.1T TInfectious Diseases – Deals of the MonthT 48

T6.4T TPharmaceuticals and Healthcare, Global, Immunology Deals, December 2010T 49

T6.4.1T TImmunology – Deals of the MonthT 50

T6.5T TPharmaceuticals and Healthcare, Global, Metabolic Disorders Deals, December 2010T 51

T6.5.1T TMetabolic Disorders – Deals of the MonthT 52

T6.6T TPharmaceuticals and Healthcare, Global, Cardiovascular Deals, December 2010T 53

T6.6.1T TCardiovascular – Deals of the MonthT 54

T6.7T TPharmaceuticals and Healthcare, Global, Dermatology Deals, December 2010T 55

T6.7.1T TDermatology – Deals of the MonthT 56

T7T TDeal Summary by GeographyT 57

T7.1T TPharmaceuticals and Healthcare, North America, Regional Deals, December 2010T 57

T7.1.1T TNorth America – Deals of the MonthT 58

T7.2T TPharmaceuticals and Healthcare, Europe, Regional Deals, December 2010T 59

T7.2.1T TEurope – Deals of the MonthT 60

T7.3T TPharmaceuticals and Healthcare, Asia-Pacific, Regional Deals, December 2010T 61

T7.3.1T TAsia-Pacific – Deals of the MonthT 62

T7.4T TPharmaceuticals and Healthcare, Rest of the World Deals, December 2010T 63

T7.4.1T TRest of the World – Deals of the MonthT 64

T8T TPharmaceuticals and Healthcare, Top AdvisorsT 65

T8.1T TPharmaceuticals and Healthcare, Global, Top Financial Advisors, M&A, July 2010 – December 2010T 65

T8.2T TPharmaceuticals and Healthcare, Global, Top Financial Advisors, Equity Offerings, July 2010 – December 2010T 66

T9T TFurther InformationT 67

T9.1T TMethodologyT 67

T9.2T TAbout GlobalDataT 68

T9.3T TContact UsT 68

T9.4T TDisclosure informationT 68

T9.5T TDisclaimerT 68

List of Tables

1.1 9BList of Tables

TU

Table 1: Pharmaceuticals and Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), July 2010 – December 2010UT 9

TU

Table 2: Pharmaceuticals and Healthcare, Global, Top Deals, December 2010UT 10

TU

Table 3:

List of Figures

1.2 10BList of Figures

TU

Figure 1:UT TUPharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), July 2010 – December 2010UT 8

TU

Figure 2:UT TUPharmaceuticals and Healthcare, Global, Number Of Deals (%) and Deal Values (%),December 20

$1,000

Can be used by individual purchaser only

$3,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about our multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

Every customer’s requirement is unique. We understand that and can customize the report basis your exact research requirements pertaining to market insights, innovation insights, strategy and planning, and competitive intelligence. You can also avail the option of purchasing stand-alone sections of the report or request for a country specific report.

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Testimonial

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods
Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.

Pharmaceuticals
New
Net Present Value Model: (borneol + edaravone)
$500 | November 2022
Pharmaceuticals
New
Net Present Value Model: (Aspirin + Dipyridamole) ER
$500 | November 2022